PTU - Polskie Towarzystwo Urologiczne
list of articles:

p53 EXPRESSION IN URINARY BLADDER CANCER. AN INITIAL STUDY
Article published in Urologia Polska 2000/53/1.

authors

Anna Kołodziej 2, Danuta Du¶ 1, Janusz Dembowski 2, Romuald Zdrojowy 2, Tomasz Szydełko 2, Jerzy Lorenz 2
1 Zakład Immunologii Nowotworów Instytut Immunologii i Terapii Do¶wiadczalnej PAN we Wrocławiu
Kierownik Instytutu: prof. dr hab. C. Radzikowski
2 Katedra i Klinika Urologii Akademii Medycznej we Wrocławiu
Kierownik Kliniki: prof. dr hab. J. Lorenz

keywords

bladder carcinoma p53 expression

summary

The aim of the study. p53 tumor suppressor gene is considered to play a
significant role in carcinogenesis. Mutations in the p53 are the most fre±uent
genetic abnormalities encountered in human malignancies. Our aim was to
investigate the expression of p53 oncoprotein in superficial and invasive
transitional cell bladder cancer (TCC) as well as its correlation with established
Prognostic factors, such as histologic grade, tumor stage, DNA content and
survival.
Results. p53 tumor suppressor protein was overexpressed in 46.3% of TCC
of 32 cases and more fre±uently in invasive than superficial TCCs and
undetectable in the tumor adjacent to normal tissue. p53 positivity was related
to the degree of differentiation and with the stage of the disease. p53
overexprssion demonstrated a correlation with DNA ploidy. There was no
correlation of recurrence related to p53 positive superficial tumors. There was
a correlations with progression. When we combined ploidy and p53 status, we
realized that the subset of patients with aneuploidy and p53 positivity had the
worst prognosis.
Conclusions. p53 expression and ploidy DNA estimations are useful methods
in prognosis for bladder cancer patients. Aneuploidy and p53 expression may
indicate high risk ofthe recurrence and progression.

references

  1. [1] Casetta, G., Gontero, R, Russo, R., Tizzani, A.: p53 ekspression compared
  2. with other prognostic factors in OMS grade-I, stage Tg transitional cell carcinoma of
  3. the bladder. Eur. Urol. 1997,32,229-236.
  4. [2] Dowell, S. R, Wilson, R O., Derias, N. W., et al.: Clinical utylity ofthe
  5. immunocytochemical detection ofthe p53 protein in cytological specimens. Cancer
  6. Res. 1994, 54, 2914-2918.
  7. [3] Glick, S. H., Howell, L. R, Devere-White, R. W.: Relationship ofp53 and
  8. bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J.
  9. Urol. 1996,155,1754-1757.
  10. [4] Herr, H. H., Bajorin, D. D., Scher, H. I., Cordon-Cardo, C, Reuter, V.:
  11. Can p53 help select patients with invasive bladder cancer for bladder preseruation?
  12. J. Urol., 1999,161, 20-23.
  13. [5] Jahnson, S., Risberg, B., Kerlsson, M. G.: p53 and Rb immunostaining in
  14. locally advanced bladder cancer. Eur. Urol. 1995, 28,135-142.
  15. [6] Kołodziej, A., Du¶, D., Lorenz, J.: Ploidia DNA a czas przeżycia pacjentów z
  16. guzami pęcherza moczowego; badania retrospektywne. Urol. Pol. 1997,1,19.
  17. [7] Kołodziej,.. A., Du¶, D., Lorenz, J.: Warto¶ć prognostyczna ploidii DNA w
  18. rakach pęcherza moczowego. Urol. Pol. 1996,4,12.
  19. [8] Lipponen, P. K.: Over-expression ofp53 nuclear oncoprotein in transitional cell
  20. bladder cancer and its prognostic value. Int. J. Cancer 1993, 53,1393-1398.
  21. [9] Lowe, S., Ruley, H.: p53 dependent apopoptosis modulates the cytotoxidty of
  22. anticancer agents. Cell 1993, 74, 957-967.
  23. [10] Moch, H., Sauter, G., Mitatsh, M. J. et al.: p53 but not erbB-2 expression is
  24. associated with rapid tumour proliferation in urinary bladder cancer. Hum. Pa-
  25. thol. 1994, 25,1346-1351.
  26. [11] Morkve, O., Laerum, O. D.: Flow cytometric measurement of p53 expression
  27. and DNA content in bronchial carcinomas. Cytometry 1981,12, 438-444.
  28. [12] Ovesen, H., Horn, T., Steven, K.: Long-term efficacy of intravesical BCG for
  29. carcinoma in situ; relationship of progression to histopathological responce and p53
  30. accumulation. J. Urol. 1997,157,1655-1659.
  31. [13] Ozdemir, E., Kakehi, Y., Okuno, H., Yoshida, O.: Strong correlation of
  32. basement membrane degradation with p53 inactwation and/or MDM2 overexpres-
  33. sion in superficial urothelial carcinomas. J. Urol. 1997,158, 206-211.
  34. [14] Pfister, Ch., Buzelin, F., Casse, Ch. et al.: Comparative analysis of MiBl
  35. and p53 expression in human bladder tumors and their correlation with progression.
  36. Eur. Urol. 1998, 33, 278-284.
  37. [15] Raitanen, M. R, Tammela, T. L., Kallioinen, M., Isola, J.:p53 accumula-
  38. tion, DNA ploidy and progression of bladder cancer. J. Urol. 1997,157,1250-1253.
  39. [16] Scott, N., Sagar, P., Steward, J. et al.: p53 in colorectal cancer. Br. J. Cancer
  40. 1991, 61, 369.
  41. [17] Sherman, C. D.: Onkologia kliniczna. PZWL, Warszawa 1992.
  42. [18] Skinner, D. G., Lieskovski, G.: Management of invasive and high grade blad-
  43. der cancer. In: Diagnosis and management of genitourinary cancer. D. G. Skinner
  44. and D. G., Lieskovski (eds.),.Philadelphia 1996. W. B. Saunders Co., 295-312.
  45. [19] U. I. CC: TNM classification of malignant tumours. Geneva 1998.
  46. [20] Ye, D., Zheng, J., Qian, S., Ma, Y.: Expression of p53 product in chinese hu-
  47. man bladder human carcinoma. Urol. Res. 1993, 21, 223-226.
  48. [21] Zatoński, W.: Nowotwory zło¶liwe w Polsce w 1989 roku. ZOWzRiEN, War-
  49. szawa 1992.